bpc-157 human trials Frontiers bpc-157 clinical trials What is

We are on a mission to boost your results and wellbeing , for modern active community that wants to live life in full, embracing each day and live a life on their own terms

The biology is genuinely interesting: thymosin beta-4 triggers angiogenesis, calms inflammation by downregulating the NF-B pathway, and inhibits programmed cell death together creating a favorable environment for tissue repair (Jeffrey Peng, MD

No human trial dose exists Every dose number above comes from rodent studies scaled to a human size or from research community use

Growth factor upregulation (VEGF pathway): Also well-represented in the published literature